The present disclosure relates to oral naproxen sodium tablets comprising roller-compacted granules, methods of preparing thereof, and methods of using thereof. The naproxen sodium tablets are formulated for and prepared by dry granulation methods, specifically roller compaction. The combination of dry granulation compatible excipients with roller compaction methods results m naproxen sodium tablets that exhibit an enhanced dissolution profile and shorter disintegration time as compared to commercially available oral naproxen sodium tablets prepared by standard wet granulation methods.

Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.

There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function. The release modifying excipient blends overcome problems associated with use of Contramid, and provide a flexible platform for formulation of active pharmaceutical ingredients for controlled release applications.

The present invention relates to the use of sodium octenyl succinate starch as a binder in twin screw granulation, in particular for pharmaceutical solid dosage form and the granule obtainable by the method thereof.

The invention relates to a pharmaceutical composition containing alginate oligosaccharide diacid with formula (IV) or a pharmaceutically acceptable salt thereof, which can be used for preparing medicaments for treating Alzheimer's disease, Parkinson's disease, inflammation, pain, diabetes or vascular dementia.

##STR00001##

Provided is an orally disintegrating tablet comprising brexpiprazole or a salt thereof that rapidly disintegrates in the oral cavity while having hardness suitable for practical use.

More specifically, provided is an orally disintegrating tablet comprising (A) brexpiprazole or a salt thereof, (B) D-mannitol, (C) partially pregelatinized starch, and (D) a lubricant.

Orally adhering lozenges comprising soluble dietary fiber are provided herein. The orally adhering lozenges provided herein may be in the form of tablet-type lozenges comprising compressed powders and/or granules in at least two layers. The orally adhering lozenges include at least 30% soluble dietary fiber. The orally adhering lozenges also include an adhesive component to adhere the lozenge inside the mouth. The orally adhering lozenges are also low in cariogenic sugar, non-resistant starch, and polyols.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

A present invention relates to a natural lubricant composition, a tablet comprising a natural lubricant composition and a preparation method thereof. The Natural Lubricant composition for a tablet comprises an active lubricant ingredient selected from a corn flour, a corn starch, and an arrowroot flour. The Natural Lubricant composition for a tablet also comprises a natural oil.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In particular, the present disclosure provides a pharmaceutical composition in the form of an orally disintegrating tablet. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect. The disclosure further provides a discriminating in vitro dissolution characterization method.